GC1102 80,000 IU
Sponsors
Green Cross Corporation
Conditions
Hepatitis B Infection
Phase 2
A Phase 2 Study of GC1102 (Recombinant Hepatitis B Immunoglobulin) in HBV-related Liver Transplant Recipients
CompletedNCT02304315
Start: 2015-02-28End: 2016-05-31Updated: 2016-06-30
HBV-associated Liver Transplant(LT) Patients by IV Injecting GC1102
NCT03519113
Start: 2018-03-29End: 2022-09-30Target: 186Updated: 2020-01-30